Legal Representation
Attorney
Rebecca Liebowitz
USPTO Deadlines
Application History
32 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 14, 2025 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Oct 14, 2025 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Oct 3, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 3, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Oct 3, 2024 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Oct 3, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 14, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 13, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Mar 13, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Mar 13, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 21, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 19, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Sep 19, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Sep 19, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 9, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 7, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Dec 7, 2022 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Dec 7, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 18, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 23, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 23, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 3, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 21, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 9, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 8, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 8, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 25, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 25, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 25, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 22, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 5, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 2, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Engineered cells for scientific, laboratory or medical research; medically engineered cells for scientific and research use in targeted drug delivery for a wide variety of pharmaceuticals
Class 005
Cells for medical or clinical use; biological, medicinal and pharmaceutical preparations for the treatment of genetic diseases and disorders; Engineered cells for medical or clinical use, namely, for creating cell and gene therapies for treatment of medical conditions; Living cells for medical use; Drug delivery agents in the form of medically engineered cells for use in targeted drug delivery for a wide variety of pharmaceuticals; medically engineered cells for medical use in targeted drug delivery for a wide variety of pharmaceuticals; cell biological products for medical purposes, namely, induced pluripotent stem cells; Pluripotent stem cells for medical or veterinary use for cell and gene therapies
Class 042
Research and development in the field of cells for medical or clinical use; research and development in the fields of genetic diseases and disorders; pharmaceutical drug development services; Clinical research in the field of personalized therapies and universal therapies through cellular and genome modification; research and development services in the field of gene editing, genome modification, cell engineering, cellular therapy and gene therapy; medical and scientific laboratory services, namely, development of induced pluripotent stem cells; scientific research on the development and production of pluripotent stem cells
Classification
International Classes
001
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"